2023 ASCO

Critical Updates in Kidney, Prostate, and Bladder Cancer from ASCO 2023 with Dr. Toni Choueiri

Discussing GU (Genitourinary) Cancer ASCO 2023 Highlights, focusing on practice changing studies with Dr. Toni Choueiri, Director, Lank Center for Genitourinary Oncology and Professor of Medicine at Harvard Medicine School – Dana-Farber Cancer Institute.

Covering four important studies:

– TALAPRO-2: Ph3 study of talazoparib + enzalutamide vs placebo + enzalutamide as first-line (1L) treatment for mCRPC with homologous recombination repair (HRR) gene alterations

– CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab vs sunitinib in pts with advanced renal cell carcinoma

– CONTACT-03: efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior checkpoint inhibitor in metastatic renal cell carcinoma

– THOR: Erdafitinib vs chemo in pts with advanced or metastatic urothelial cancer with select FGFR alteration

2023 ASCO

Lung Cancer ASCO 2023 Highlights with Dr. Charu Aggarwal

Discussing Lung Cancer ASCO 2023 Highlights, focusing on practice changing studies with Dr. Charu Aggarwal, Director, Precision Oncology Innovation, Associate Professor of Lung Cancer Excellence at Penn Medicine. Covering three important studies:

– ADAURA trial update with increase OS with adjuvant Osimertinib

– KEYNOTE 789 – Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant

– KEYNOTE 671 – Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC

2023 ASCO

Breast Cancer ASCO 2023 Highlights with Dr. Stephanie Graff

Discussing Breast Cancer ASCO 2023 Highlights, focusing on practice-changing studies with Dr. Stephanie Graff, Director of Breast Oncology, Associate Professor of Medicine, Lifespan Cancer Institute, Brown University. Covering three important studies:

– NATALEE Phase III study of ribociclib (RIBO) + endocrine therapy (ET) in HR+ patients

– SONIA challenging the need for first-line use of a CDK4/6 Inhibitor in HR+ advanced breast cancer patients

– X-7/7 trial evaluating fixed-dose capecitabine compared to standard dose capecitabine in metastatic breast cancer

Subscribe Now


Dr. Rahul

Dr. Rahul is a Chief of Medical Oncology, making up one-half of the ‘Oncology Brothers.’ He is a valued member of the Guthrie Corning Cancer Center, contributing his extensive knowledge of technology